期刊文献+

多发性骨髓瘤生物学研究与新药靶向治疗 被引量:3

原文传递
导出
摘要 多发性骨髓瘤(MM)是一种主要侵犯中老年人群的恶性单克隆性浆细胞疾病。MM细胞的某些特征类似于长命的后生发中心浆细胞,如具有较强骨髓依赖性与广泛的Ig基因体细胞高频突变。但与终末分化生理性浆细胞不同,1%-3%MM细胞处于分裂周期;部分MM细胞(CD19-CD45。“CD38’CD138’)与肿瘤干细胞类似,保留着极高的增殖潜能。临床上,MM主要表现为溶骨病变、贫血、免疫缺陷及肾功能不全。现代治疗手段并没有从根本改变上MM的不可治愈性.只是将患者的平均生存期由3年延至6年以上。
作者 陈协群
出处 《中华血液学杂志》 CAS CSCD 北大核心 2013年第4期288-289,共2页 Chinese Journal of Hematology
  • 相关文献

同被引文献33

  • 1李娟.难治、复发多发性骨髓瘤治疗进展[J].国际输血及血液学杂志,2007,30(4):291-296. 被引量:4
  • 2Berenson JR, Yellin O, Bessudo A, et al. Phase Ⅰ/Ⅱ trial assessing bendamustine plus bortezomib combination therapy for the treat- ment of patients with relapsed or refractory multiple myeloma[J ]. Br J Haematol, 2013, 160(3) : 321 - 330.
  • 3Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma [J ]. Leukemia, ZOO6, 20 (9):1 467-1 473.
  • 4Harousseau JL, Attal M, Avet - Loiseau H, et al. Bortezomib plusdexamethasome is superior to vincristine plus doxorubicin plus dexamethasome as inductiontreatment prior to autologous stem - cell transplantation in newly diagnosed multiple myeloma: results of she IFM 2005 - 01 phase lII trial[J]. J Clin Oncol, 2010, 28 (30):4 621-4 629.
  • 5Morgan GL, Davies FE, Gregory WM, et al. First - line treat- ment with zoledronic acid as compared with clodronic acid in mul- tiple myeloma(MRC Myeloma IX):a randomised controlled trial [J] . Lancet, 2010, 376(9 757):1 989- 1 999.
  • 6Weintraub B. Trials define anti - tumor effects of anti - resorptive agents: denosumab ahead of zoledronate 2 to 1 [J ]. BioDrugs, 2011 ,25(2):135- 138.
  • 7Koren J, Spicka I , Straub J, et al, Retrospective analysis of the results of high - dose chemotherapy with the support of autolo- gous blood stem cells in patients with multiple myeloma. The expe- rience of a single centre[ J ]. Prague Med Rep, 2010, 111 (3):207 -218.
  • 8Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma[J]. Chn Exp Med, 2007, 7:83- 97.
  • 9Stringer S, Basnayake K, Hutchison C, et al. Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney[J]. Bone Marrow Res, 2011,4 : 493 -697.
  • 10Morabito F, Gentile M, Ciolli S, et al. Safety and efficacy of borte- zomib- based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA[J]. Eur J Haematol, 2010, 84 : 223 - 228.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部